Lindahl has assisted Calliditas Therapeutics AB (publ) in an exclusive in-licensing of the drug Budenofalk 3 mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma GmbH. The agreement covers all indications for the US market, excluding orphan drug indications that do not target the liver. Initially, Calliditas will leverage Dr. Falk’s clinical trial data and expertise in liver indications, such as autoimmune hepatitis (AIH), with a view to accelerating approval and market access. AIH is an orphan liver disease which Calliditas estimates affects about 60 – 80,000 people in the US and for which there is currently no approved treatment. The total deal value amounts to EUR 40 million (approximately MSEK 428), including future sales milestones and comes with typical royalties.
Lindahl’s team consisted of Hugo Norlén, Erika Svensson, Michael Edquist, Carolin Martinez and Monica Lindström.
For more information, see the press release from Calliditas.